定性影像基因组学:BI-RADS钙化描述符与Oncotype DX导管原位癌评分所评估复发风险的关联
本研究纳入58例以钙化为表现、已行Oncotype DX乳腺导管原位癌检测的导管原位癌女性,评估治疗前BI-RADS乳腺X线钙化形态、分布及最大跨度与导管原位癌评分的关联。无定形钙化的校正平均评分最低,细多形性和细线样或细线样分支状钙化与中高风险复发(评分≥39)的校正比值比显著升高相关。作者认为乳腺X线特征可能是导管原位癌复发的潜在生物标志物,有助于个体化治疗决策。
要点
- 无定形钙化的校正平均导管原位癌评分最低,细多形性和细线样或细线样分支状钙化评分更高。
- 细多形性钙化与中高风险复发(评分≥39)的校正OR=53.1(p=0.01)。
- 细线样或细线样分支状钙化与中高风险复发的校正OR=24.0(p=0.04),均以无定形钙化为参照。
核心结论
- 无定形钙化形态的女性导管原位癌评分最低,细多形性和细线样或细线样分支状形态与中高风险复发(评分≥39)的较高比值比相关;作者认为乳腺X线特征可能是导管原位癌复发的潜在生物标志物,并可能有助于个体化治疗决策。
研究设计与样本
- 研究纳入58例诊断为导管原位癌、表现为钙化且已有Oncotype DX乳腺导管原位癌检测结果的女性,收集治疗前BI-RADS乳腺X线钙化形态、分布和最大跨度,采用logistic回归模型评估钙化描述符与导管原位癌评分的关联,所有分析均校正患者年龄、导管原位癌分级和孕激素受体状态。
关键影像表现/征象
- 在证实为导管原位癌的可疑钙化中,形态为无定形者占19.0%,粗大不均质者占25.9%,细多形性者占39.7%,细线样或细线样分支状者占15.5%。
- 按钙化形态对应的平均导管原位癌评分分别为无定形22.3、粗大不均质35.5、细多形性36.7、细线样或细线样分支状44.1。
- 无定形钙化形态的校正平均导管原位癌评分显著低于细多形性形态(p=0.01)和细线样或细线样分支状形态(p=0.02)。
诊断标准与关键数值
- 中高风险复发定义为导管原位癌评分≥39。
- 以无定形钙化为参照,细多形性钙化者中高风险复发的校正OR=53.1(p=0.01)。
- 以无定形钙化为参照,细线样或细线样分支状钙化者中高风险复发的校正OR=24.0(p=0.04)。
临床应用与阅片要点
- 阅片时按BI-RADS记录钙化形态、分布和最大跨度,本研究显示形态与导管原位癌评分相关。
- 作者认为乳腺X线特征可能是导管原位癌复发的潜在生物标志物,并可能有助于个体化治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Treatment of ductal carcinoma in situ (DCIS) is controversial given the variable recurrence and progression to invasive carcinoma. Identifying women who would benefit from adjuvant radiation therapy on the basis of their recurrence risk may allow more individualized management strategies. The Oncotype DX Breast DCIS Score-which we refer to here as the "DCIS score"-is a validated surrogate marker of local recurrence. This study evaluated the association between BI-RADS mammographic calcification descriptors and the DCIS score.
MATERIALS AND METHODS: Fifty-eight women diagnosed with DCIS presenting with calcifications who had Oncotype DX Breast DCIS assay results were identified. Pretreatment BI-RADS mammographic calcification features were collected including morphology, distribution, and maximum span. The association between calcification descriptors and DCIS score was assessed with logistic regression modeling. Mean DCIS scores were calculated for calcification features significantly associated with DCIS score. All analyses were adjusted for patient age, DCIS grade, and progesterone receptor status.
RESULTS: Of the suspicious calcifications that proved to represent DCIS, 19.0% were amorphous; 25.9%, coarse heterogeneous; 39.7%, fine pleomorphic; and 15.5%, fine linear or fine linear branching in morphology. The mean DCIS scores by calcification morphology were 22.3, 35.5, 36.7, and 44.1, respectively. Amorphous calcification morphology had a significantly lower adjusted mean DCIS score compared with fine pleomorphic morphology (p = 0.01) and fine linear or fine linear branching morphology (p = 0.02). The adjusted odds ratio (OR) of intermediate or high risk of recurrence (defined as a DCIS score ≥ 39) was significantly higher for women with fine pleomorphic calcifications (OR = 53.1, p = 0.01) and for those with fine linear or fine linear branching calcifications (OR = 24.0, p = 0.04) than for women with amorphous calcifications.
CONCLUSION: Women with amorphous calcification morphology had the lowest DCIS scores compared with women with fine pleomorphic and fine linear or fine linear branching morphologies. Both fine pleomorphic and fine linear or fine linear branching morphologies were associated with higher odds of intermediate or high risk of recurrence. These findings suggest mammographic features are potential biomarkers of DCIS recurrence and could help individualize treatment decisions.
引用
- Woodard GA, Price ER. Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score. AJR Am J Roentgenol. 2019. PMID: 30714832. doi:10.2214/AJR.18.20306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。